Secondary HLH/MAS masterclass
On demand masterclass: Fabrizio de Benedetti on diagnosing and treating secondary HLH/MAS
Chapters
00.05 Solving the diagnostic puzzle of secondary HLH/MAS
17:34 Harnessing biomarkers in secondary HLH/MAS
33:38 Treatment pathways for secondary HLH/MAS
“Early recognition and timely intervention are critical to improving outcomes in HLH/MAS.” Watch this masterclass, presented by Fabrizio de Benedetti, to deepen your understanding of the diagnosis, biomarkers, and treatment strategies for secondary hemophagocytic lymphohistiocytosis / macrophage activation syndrome (HLH/MAS). This three-part series offers expert insights into managing this often underdiagnosed, rapidly progressive, and life-threatening hyperinflammatory syndrome.
Watch now to:
- Recognize the urgency of HLH/MAS and its potential for rapid clinical progression
- Apply biomarker-driven stratification to assess disease severity and monitor treatment response
- Assess how targeted therapies, including IL-1 inhibitors and IFN-γ blockade, are reshaping the treatment landscape for both pediatric and adult patients
Meet the expert
Fabrizio de Benedetti, MD, PhD
Fabrizio de Benedetti is a pediatric rheumatologist who serves as Director of the Division of Rheumatology and Head of the Laboratory of Immuno-Rheumatology at Ospedale Pediatrico Bambino Gesù in Rome, Italy. He is also Professor of Pediatric Rheumatology at the Universities Tor Vergata and La Sapienza.
De Benedetti’s work focuses on both clinical and translational research in pediatric rheumatology. He has been the principal investigator for several pivotal phase 2/3 clinical trials of novel targeted therapies in pediatric rheumatic diseases, including Still’s disease, polyarticular juvenile idiopathic arthritis, macrophage activation syndrome, familial Mediterranean fever, mevalonate kinase deficiency, and tumor necrosis factor receptor–associated periodic syndrome.
Disclosures: Abbott, Bristol Myers Squibb, Novartis, Novimmune, Pfizer, Roche, and Sobi.
This content has been developed independently by Medthority who previously received educational funding from Sobi in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.